secwatch.observer — SEC 8-K summary
======================================

Issuer:     PALATIN TECHNOLOGIES INC (PTN)
CIK:        0000911216
Form:       8-K
Filed at:   2023-05-30T23:59:59+00:00
Accession:  0001654954-23-007322
Event type: other_material
Sentiment:  neutral
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Palatin presents preclinical data on PL8177 in diabetic nephropathy; Phase 2 BREAKOUT study enrolling
--------------------------------------------------------------------------------

- PL8177 preserved podocyte count and WT1 expression in diabetic rats vs. vehicle.
- Glomerular hypertrophy trended toward reduction in PL8177-treated kidneys.
- Data presented at International Podocyte Conference, May 24-26, 2023 in Philadelphia.
- Phase 2 BREAKOUT study (bremelanotide) for diabetic kidney disease now enrolling (NCT05709444).
- CEO cites melanocortin system potential for new inflammatory disease treatments.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/911216/000165495423007322/0001654954-23-007322-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/911216/000165495423007322/ptn_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-007322

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer